RG 7652
Alternative Names: MPSK-3169A; RG-7652Latest Information Update: 05 Nov 2023
At a glance
- Originator Genentech; Roche
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary disorders; Hyperlipidaemia; Metabolic disorders
Most Recent Events
- 24 Jul 2014 Discontinued - Phase-I for Metabolic disorders in Switzerland (unspecified route)
- 24 Jul 2014 Discontinued - Phase-II for Coronary disorders and Hyperlipidaemia in USA, Canada, Czech Republic, Germany, Hungary, New Zealand, Norway, Slovakia and South Africa (SC)
- 31 Jul 2013 Genentech completes the phase II EQUATOR trial in Coronary disorders and Hyperlipidaemia in USA, Canada, Czech Republic, Germany, Hungary, New Zealand, Norway, Slovakia and South Africa (NCT01609140)